{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:10:01Z","timestamp":1772356201048,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.joms.2008.12.006","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T04:15:24Z","timestamp":1239768924000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"S","title":["Alternative Indications for Bisphosphonate Therapy"],"prefix":"10.1016","volume":"67","author":[{"given":"Regina","family":"Landesberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney","family":"Eisig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilene","family":"Fennoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethel","family":"Siris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2008.12.006_bib1","article-title":"Oral and Maxillofacial Pathology","author":"Neville","year":"2008"},{"key":"10.1016\/j.joms.2008.12.006_bib2","article-title":"Oral Pathology: Clinical Pathologic Correlations","author":"Regezi","year":"2007"},{"key":"10.1016\/j.joms.2008.12.006_bib3","article-title":"Contemporary Oral and Maxillofacial Pathology","author":"Sapp","year":"2003"},{"key":"10.1016\/j.joms.2008.12.006_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0030-4220(92)90137-F","article-title":"Cherubism: Diagnosis, treatment, and comparison with central giant cell granulomas and giant cell tumors","volume":"73","author":"Kaugars","year":"1992","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.joms.2008.12.006_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0030-4220(88)90094-1","article-title":"A clinical and histomorphologic comparison of the central giant cell granuloma and the giant cell tumor","volume":"66","author":"Auclair","year":"1988","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.joms.2008.12.006_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1600-0714.1997.tb00451.x","article-title":"Central giant cell granulomas of the jaws: Phenotype and proliferation-associated markers","volume":"26","author":"O'Malley","year":"1997","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.joms.2008.12.006_bib7","first-page":"75","article-title":"Intralesional corticosteroid injection for central giant cell granuloma: A case report and review of the literature","volume":"47","author":"Sezer","year":"2005","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0266-4356(93)90168-V","article-title":"Central giant cell granulomas of the jaws regress with calcitonin therapy","volume":"31","author":"Harris","year":"1993","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2008.12.006_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0901-5027(99)80086-1","article-title":"Treatment of central giant cell granuloma of the jaw with calcitonin","volume":"28","author":"de Lange","year":"1999","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2008.12.006_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/joms.2003.50129","article-title":"Calcitonin therapy for central giant cell granuloma","volume":"61","author":"Pogrel","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2008.12.006_bib11","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.joms.2007.04.024","article-title":"Discussion: Adjuvant antiangiogenic therapy for giant cell tumors of the jaws","volume":"65","author":"Pogrel","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"6 Pt 1","key":"10.1016\/j.joms.2008.12.006_bib12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1542\/peds.103.6.1145","article-title":"Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a","volume":"103","author":"Kaban","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.joms.2008.12.006_bib13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/joms.2002.34975","article-title":"Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws","volume":"60","author":"Kaban","year":"2002","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2008.12.006_bib14","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ijom.2006.08.010","article-title":"Management of giant cell lesions","volume":"35","author":"Kaban","year":"2006","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2008.12.006_bib15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.joms.2007.03.030","article-title":"Adjuvant antiangiogenic therapy for giant cell tumors of the jaws","volume":"65","author":"Kaban","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2008.12.006_bib16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.tripleo.2004.11.024","article-title":"Complications of alpha-interferon therapy for aggressive central giant cell lesion of the maxilla","volume":"100","author":"Goldman","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2008.12.006_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00432-008-0370-x","article-title":"Giant cell tumor of bone: Treatment and outcome of 214 cases","volume":"134","author":"Balke","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.joms.2008.12.006_bib18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bone.2007.08.038","article-title":"Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case-control study","volume":"42","author":"Tse","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"10.1016\/j.joms.2008.12.006_bib20","first-page":"332","article-title":"Osteogenesis imperfecta: Anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy","volume":"95","author":"Vallo","year":"2006","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jmg.28.7.433","article-title":"Osteogenesis imperfecta: Translation of mutation to phenotype","volume":"28","author":"Byers","year":"1991","journal-title":"J Med Genet"},{"key":"10.1016\/j.joms.2008.12.006_bib22","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1359\/jbmr.2000.15.9.1650","article-title":"Type V osteogenesis imperfecta: A new form of brittle bone disease","volume":"15","author":"Glorieux","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","article-title":"Osteogenesis imperfecta type VI: A form of brittle bone disease with a mineralization defect","volume":"17","author":"Glorieux","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S8756-3282(02)00790-1","article-title":"Osteogenesis imperfecta type VII: An autosomal recessive form of brittle bone disease","volume":"31","author":"Ward","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic administration of pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2008.12.006_bib26","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.joms.2008.12.006_bib27","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: Mode of action and pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.joms.2008.12.006_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: An update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.joms.2008.12.006_bib29","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.joms.2008.12.006_bib30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jpeds.2008.05.010","article-title":"The growing skeleton is a busy place\u2014Can biochemical bone markers keep track of the action?","volume":"153","author":"Rauch","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1515\/JPEM.2008.21.1.63","article-title":"Cyclic pamidronate therapy in children with osteogenesis imperfecta: Results of treatment and follow-up after discontinuation","volume":"21","author":"Andiran","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"suppl 5","key":"10.1016\/j.joms.2008.12.006_bib32","first-page":"207","article-title":"Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta","volume":"68","author":"Cabral de Menezes Filho","year":"2007","journal-title":"Horm Res"},{"key":"10.1016\/j.joms.2008.12.006_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/JPEM.2005.18.1.43","article-title":"A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta","volume":"18","author":"DiMeglio","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.joms.2008.12.006_bib35","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00247-004-1393-3","article-title":"Bone densitometry in pediatric patients treated with pamidronate","volume":"35","author":"Grissom","year":"2005","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.joms.2008.12.006_bib36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jpeds.2005.10.041","article-title":"Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta","volume":"148","author":"Land","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib37","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bone.2006.10.010","article-title":"Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment","volume":"40","author":"Land","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib39","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1651-2227.2007.00390.x","article-title":"Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta","volume":"96","author":"Lowing","year":"2007","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib40","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/JBMR.050213","article-title":"Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome","volume":"20","author":"Munns","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib41","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","article-title":"Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate","volume":"19","author":"Munns","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib42","first-page":"1846","article-title":"Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age","volume":"85","author":"Plotkin","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2008.12.006_bib43","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/BPO.0b013e318173a923","article-title":"Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards","volume":"28","author":"Poyrazoglu","year":"2008","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.joms.2008.12.006_bib44","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","article-title":"Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation","volume":"91","author":"Rauch","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2008.12.006_bib45","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/adc.2007.125468","article-title":"Two doses of pamidronate in infants with osteogenesis imperfecta","volume":"93","author":"Senthilnathan","year":"2008","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.joms.2008.12.006_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bone.2005.07.020","article-title":"The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V","volume":"38","author":"Zeitlin","year":"2006","journal-title":"Bone"},{"issue":"suppl 2","key":"10.1016\/j.joms.2008.12.006_bib47","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","article-title":"Experience with bisphosphonates in osteogenesis imperfecta","volume":"119","author":"Glorieux","year":"2007","journal-title":"Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib48","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0022-3476(97)70074-X","article-title":"Intravenous pamidronate treatment in osteogenesis imperfecta","volume":"131","author":"Bembi","year":"1997","journal-title":"J Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib49","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bone.2006.04.004","article-title":"Vertebral morphometry in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate treatment","volume":"39","author":"Land","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0722.2008.00529.x","article-title":"Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta","volume":"116","author":"Kamoun-Goldrat","year":"2008","journal-title":"Eur J Oral Sci"},{"key":"10.1016\/j.joms.2008.12.006_bib51","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Sclerotic metaphyseal lines in a child treated with pamidronate: Histomorphometric analysis","volume":"19","author":"Rauch","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib52","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1515\/JPEM.2007.20.11.1167","article-title":"Metaphyseal sclerosis associated with bisphosphonate therapy","volume":"20","author":"Damiani","year":"2007","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.joms.2008.12.006_bib53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1359\/JBMR.051207","article-title":"Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta","volume":"21","author":"Land","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-0714.2007.00607.x","article-title":"No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates","volume":"37","author":"Malmgren","year":"2008","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.joms.2008.12.006_bib55","first-page":"537","article-title":"Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: A case series","volume":"74","author":"Schwartz","year":"2008","journal-title":"J Can Dent Assoc"},{"key":"10.1016\/j.joms.2008.12.006_bib56","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1203\/00006450-200211000-00010","article-title":"Alendronate treatment for infants with osteogenesis imperfecta: Demonstration of efficacy in a mouse model","volume":"52","author":"McCarthy","year":"2002","journal-title":"Pediatr Res"},{"key":"10.1016\/j.joms.2008.12.006_bib57","first-page":"1158","article-title":"Oral alendronate in osteogenesis imperfecta","volume":"42","author":"Unal","year":"2005","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib58","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.bpo.0000176162.78980.ed","article-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta","volume":"25","author":"Seikaly","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.joms.2008.12.006_bib59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jbspin.2004.09.005","article-title":"Effect of alendronate therapy in children with osteogenesis imperfecta","volume":"72","author":"Vyskocil","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.joms.2008.12.006_bib60","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/01.bpo.0000164871.36098.4c","article-title":"Efficacy of oral alendronate in children with osteogenesis imperfecta","volume":"25","author":"Cho","year":"2005","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.joms.2008.12.006_bib61","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1210\/jc.2004-2054","article-title":"Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I","volume":"90","author":"Ward","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2008.12.006_bib62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.rhu.0000208490.22492.09","article-title":"Alendronate treatment in osteogenesis imperfecta","volume":"12","author":"Madenci","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.joms.2008.12.006_bib63","first-page":"105","article-title":"Alendronate treatment in children with osteogenesis imperfecta","volume":"45","author":"Akcay","year":"2008","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib64","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","article-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: A 3-year randomized placebo-controlled trial","volume":"21","author":"Chevrel","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1179\/146532807X170493","article-title":"Oral bisphosphonate treatment for osteogenesis imperfecta\u2014An Indian perspective","volume":"27","author":"Shah","year":"2007","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib66","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/berh.1999.0071","article-title":"Fibrous dysplasia of bone","volume":"14","author":"Chapurlat","year":"2000","journal-title":"Baillieres Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.joms.2008.12.006_bib67","first-page":"400","article-title":"Fibrous dysplasia","volume":"69","author":"Stephenson","year":"1987","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.joms.2008.12.006_bib68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00774-005-0638-z","article-title":"Clinical approach to clarifying the mechanism of abnormal bone metabolism in McCune-Albright syndrome","volume":"24","author":"Yamamoto","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2008.12.006_bib69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.berh.2007.11.004","article-title":"Fibrous dysplasia of bone and McCune-Albright syndrome","volume":"22","author":"Chapurlat","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"suppl 2","key":"10.1016\/j.joms.2008.12.006_bib70","doi-asserted-by":"crossref","first-page":"P114","DOI":"10.1359\/jbmr.06s222","article-title":"Medical therapy in adults with fibrous dysplasia of bone","volume":"21","author":"Chapurlat","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib71","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib72","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: Long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib73","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S8756-3282(03)00221-7","article-title":"Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia","volume":"33","author":"Parisi","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib74","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","volume":"382","author":"Lane","year":"2001","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.joms.2008.12.006_bib75","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1177\/014556130608501012","article-title":"Fibrous dysplasia of the frontal bone","volume":"85","author":"Hempel","year":"2006","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.joms.2008.12.006_bib76","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1651-2227.2008.00643.x","article-title":"Gaucher disease: Improving management","volume":"97","author":"Bembi","year":"2008","journal-title":"Acta Paediatr Suppl"},{"issue":"suppl 1","key":"10.1016\/j.joms.2008.12.006_bib77","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: A review","volume":"75","author":"Wenstrup","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1016\/j.joms.2008.12.006_bib78","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: Alendronate disodium improves bone mineral density in adults receiving enzyme therapy","volume":"104","author":"Wenstrup","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.joms.2008.12.006_bib79","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0140-6736(84)92579-0","article-title":"Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate","volume":"8401","author":"Harinck","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.joms.2008.12.006_bib80","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJM199709043371015","article-title":"Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement","volume":"337","author":"Ciana","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2008.12.006_bib81","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1542\/peds.94.3.385","article-title":"Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease","volume":"94","author":"Samuel","year":"1994","journal-title":"Pediatrics"},{"key":"10.1016\/j.joms.2008.12.006_bib82","first-page":"329","article-title":"Subacute and chronic \u201csymmetrical\u201d osteomyelitis","volume":"15","author":"Giedion","year":"1992","journal-title":"Ann Radiol (Paris)"},{"key":"10.1016\/j.joms.2008.12.006_bib83","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1302\/0301-620X.75B4.8331113","article-title":"Chronic multifocal osteomyelitis","volume":"75","author":"Carr","year":"1993","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.joms.2008.12.006_bib84","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01241398-198609000-00010","article-title":"Chronic recurrent multifocal osteomyelitis: A distinct clinical entity","volume":"6","author":"Gamble","year":"1984","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.joms.2008.12.006_bib85","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1542\/peds.113.4.e380","article-title":"Chronic recurrent multifocal osteomyelitis of the spine and mandible: Case report and review of the literature","volume":"113","author":"Chun","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.joms.2008.12.006_bib86","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s004310000500","article-title":"Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: A report of ten cases and review of the literature","volume":"159","author":"Beretta-Piccoli","year":"2000","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1079-2104(05)80332-4","article-title":"Possible identity of diffuse sclerosing osteomyelitis and chronic recurrent multifocal osteomyelitis","volume":"80","author":"Suei","year":"1995","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2008.12.006_bib88","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jpeds.2007.08.047","article-title":"Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis","volume":"152","author":"Simm","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.joms.2008.12.006_bib89","first-page":"707","article-title":"Childhood chronic recurrent multifocal osteomyelitis: Pamidronate therapy decreases pain and improves vertebral shape","volume":"35","author":"Gleeson","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joms.2008.12.006_bib90","first-page":"1585","article-title":"Pamidronate treatment of chronic noninfectious inflammatory lesions of the mandible in children","volume":"34","author":"Compeyrot-Lacassagne","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joms.2008.12.006_bib91","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tripleo.2006.09.021","article-title":"Remarkable response of juvenile diffuse sclerosing osteomyelitis of mandible to pamidronate","volume":"104","author":"Yamazaki","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2008.12.006_bib92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1054\/ijom.2001.0061","article-title":"Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible","volume":"30","author":"Montonen","year":"2001","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"suppl 2","key":"10.1016\/j.joms.2008.12.006_bib93","first-page":"99","article-title":"Wear particles","volume":"88","author":"Jacobs","year":"2006","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.joms.2008.12.006_bib94","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00003086-200403000-00003","article-title":"Mechanisms of failure of total hip replacements: Lessons learned from retrieval studies","volume":"420","author":"Hirakawa","year":"2004","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.joms.2008.12.006_bib95","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1359\/jbmr.2001.16.11.2126","article-title":"Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study","volume":"16","author":"Venesmaa","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2008.12.006_bib96","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.2106\/00004623-200311000-00009","article-title":"The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty","volume":"85-A","author":"Wang","year":"2003","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.joms.2008.12.006_bib97","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01.blo.0000201170.57141.66","article-title":"Osseointegration of cementless implants with different bisphosphonate regimens","volume":"447","author":"Eberhardt","year":"2006","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.joms.2008.12.006_bib98","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2106\/JBJS.G.00635","article-title":"Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatite-coated implants in ovariectomized rats","volume":"90","author":"Nakamura","year":"2008","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.joms.2008.12.006_bib99","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2004.12.017","article-title":"The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats","volume":"37","author":"Kurth","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/17453670710013979","article-title":"Surface-bound bisphosphonates enhance screw fixation in rats\u2014Increasing effect up to 8 weeks after insertion","volume":"78","author":"Wermelin","year":"2007","journal-title":"Acta Orthop"},{"key":"10.1016\/j.joms.2008.12.006_bib101","doi-asserted-by":"crossref","first-page":"10","DOI":"10.22203\/eCM.v016a02","article-title":"Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model","volume":"16","author":"Stadelmann","year":"2008","journal-title":"Eur Cell Mater"},{"key":"10.1016\/j.joms.2008.12.006_bib102","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2106\/JBJS.G.00409","article-title":"Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite","volume":"90","author":"Suratwala","year":"2008","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.joms.2008.12.006_bib103","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bone.2007.10.013","article-title":"Stainless steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone","volume":"42","author":"Wermelin","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.joms.2008.12.006_bib104","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0736-0266(01)00155-3","article-title":"A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles","volume":"20","author":"Iwase","year":"2002","journal-title":"J Orthop Res"},{"key":"10.1016\/j.joms.2008.12.006_bib105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/000164702317281369","article-title":"Reduction of instability-induced bone resorption using bisphosphonates: High doses are needed in rats","volume":"73","author":"Astrand","year":"2002","journal-title":"Acta Orthop Scand"},{"key":"10.1016\/j.joms.2008.12.006_bib106","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/jor.20620","article-title":"Differential effects of biologic versus bisphosphonate inhibition of wear debris-induced osteolysis assessed by longitudinal micro-CT","volume":"26","author":"Tsutsumi","year":"2008","journal-title":"J Orthop Res"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027823910801834X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027823910801834X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:26:37Z","timestamp":1759508797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027823910801834X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S027823910801834X"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2008.12.006","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alternative Indications for Bisphosphonate Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2008.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}